194 related articles for article (PubMed ID: 28148945)
1. FDA approves splice-modulating drug.
Mullard A
Nat Rev Drug Discov; 2017 Feb; 16(2):77. PubMed ID: 28148945
[No Abstract] [Full Text] [Related]
2. FDA approves AIDS drug.
Am Pharm; 1992 Sep; NS32(9):13-4. PubMed ID: 1332462
[No Abstract] [Full Text] [Related]
3. Market watch: Upcoming market catalysts in Q1 2014.
Stopke E
Nat Rev Drug Discov; 2014 Jan; 13(1):11. PubMed ID: 24378790
[No Abstract] [Full Text] [Related]
4. Market watch: Upcoming market catalysts in Q1 2017.
Fulton Z
Nat Rev Drug Discov; 2016 Dec; 16(1):11. PubMed ID: 28031567
[No Abstract] [Full Text] [Related]
5. FDA approves treatment IND protocol for taxol.
Clin Pharm; 1992 Nov; 11(11):912. PubMed ID: 1361164
[No Abstract] [Full Text] [Related]
6. Accelerated approval seen as triumph and roadblock for cancer drugs.
Susman E
J Natl Cancer Inst; 2004 Oct; 96(20):1495-6. PubMed ID: 15494596
[No Abstract] [Full Text] [Related]
7. Market watch: Upcoming market catalysts in Q1 2018.
Collins T
Nat Rev Drug Discov; 2018 Dec; 17(1):8-9. PubMed ID: 29282372
[No Abstract] [Full Text] [Related]
8. 2016 FDA drug approvals.
Mullard A
Nat Rev Drug Discov; 2017 Feb; 16(2):73-76. PubMed ID: 28148938
[No Abstract] [Full Text] [Related]
9. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
10. New drug awaiting FDA approval may reverse bone loss.
Mayo Clin Health Lett; 2001 Nov; 19(11):4. PubMed ID: 11692627
[No Abstract] [Full Text] [Related]
11. Breakthrough-Therapy Designation - An FDA Perspective.
Corrigan-Curay J; McKee AE; Stein P
N Engl J Med; 2018 Apr; 378(15):1457-1458. PubMed ID: 29641963
[No Abstract] [Full Text] [Related]
12. The Food and Drug Administration perspective: use of an investigational drug in a medical emergency.
Schultheis LW; Rappaport BA
Anesth Analg; 2007 Mar; 104(3):479-80. PubMed ID: 17312189
[No Abstract] [Full Text] [Related]
13. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes.
Finkelstein PE
AMA J Ethics; 2015 Dec; 17(12):1142-6. PubMed ID: 26698587
[No Abstract] [Full Text] [Related]
14. Patient group seeks overhaul of FDA clinical trial system in court.
Hede K
J Natl Cancer Inst; 2006 Sep; 98(18):1268-70. PubMed ID: 16985242
[No Abstract] [Full Text] [Related]
15. Accelerated drug approval: FDA may get tougher; companies cite hurdles.
Goozner M
J Natl Cancer Inst; 2011 Mar; 103(6):455-7. PubMed ID: 21393609
[No Abstract] [Full Text] [Related]
16. How does a drug get to phase III trials?
Reynolds T
J Natl Cancer Inst; 2000 Oct; 92(19):1555. PubMed ID: 11018084
[No Abstract] [Full Text] [Related]
17. TransMolecular receives FDA approval for 131-I-TM-601 IND application.
Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233
[No Abstract] [Full Text] [Related]
18. Regulatory watch: FDA guidance on co-developing investigational drugs.
Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094
[No Abstract] [Full Text] [Related]
19. New FDA breakthrough-drug category--implications for patients.
Darrow JJ; Avorn J; Kesselheim AS
N Engl J Med; 2014 Mar; 370(13):1252-8. PubMed ID: 24670173
[No Abstract] [Full Text] [Related]
20. Accelerated approval regulations may need overhaul, panel suggests.
Finkelstein JB
J Natl Cancer Inst; 2005 Dec; 97(24):1802-4. PubMed ID: 16368938
[No Abstract] [Full Text] [Related]
[Next] [New Search]
